Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Yearly performance of total market index funds provides a broad view of winners and laggards. Use these insights to adjust your exposure today.
28,320 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A strong earnings beat and improving fundamentals pushed Barrick's stock higher. This article breaks down the factors...
Best Buy surprised investors with a solid earnings beat and improving margins, sending the stock higher. This article...
Qualcomm rolls out a five year plan to compete with Nvidia in AI data center chips, aiming for multi billion dollar A...
As 2025 closes, star bulk (sblk) enters a new chapter. This guide breaks down the Q4 2025 results, fleet strategy, ba...
Microsoft shares fell Tuesday as investors reassessed the cost of OpenAI bets and growing capital needs, even after a...
Nexxn (NEXN) 2026 earnings signal how the company is navigating growth, profitability, and capital allocation. This g...
Broadcom shares rose in early trading after Alphabet unveiled an up-to-$80 billion plan to expand AI infrastructure, ...
PTIR's double-leveraged bet on Palantir underperformed the stock by nearly half over the past year, underscoring the ...
Bitcoin slides toward $60,000 raise fresh concerns for BLOK, the blockchain-focused ETF. This report explains potenti...
Navitas NVTS and ON Semiconductor are capturing attention as AI data-center demand climbs. Analysts see a potential r...
Investors wonder if late sandisk stock is still worth buying as NAND memory underpins AI growth. This guide breaks do...